Mobile website
Archive > Volume 22 Issue 6 > 2015,22(6):765-772. DOI:10.3872/j.issn.1007-385X.2015.06.015 Prev Next
Clinical Research
Clinical efficacy and prognostic analysis of the combination therapy with dendritic cells and cytokine-induced killer cells in the treatment of 39 patients with moderate and advanced cervical cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To evaluate the safety and clinical efficacy of the dendritic cells (DCs) and cytokine-induced killer (CIK) cells combination therapy in the treatment of moderate and advanced cervical cancer and analyze the prognostic factors. Methods: Thirty-nine patients with stage Ⅱb～Ⅳ cervical cancer who received DC-CIK cells treatment in the No. 81 hospital of PLA from Aug. 2011 to Dec. 2014 were enrolled into this retrospective analysis. Clinical response and changes of lymphocyte subsets and serum levels of tumor makers following the treatment were evaluated. Single and multiple-variable analyses were performed to identify the prognostic factors.Results: For the 39 patients received our DC-CIK cells immunotherapy, the overall response rate and the disease control rate were 20.5% and 66.7% respectively. Their 1-year overall survival rate was 61%, and both 2-year and 3-year survival rates were 46%. While there were no significant changes in lymphocyte subsets and SCCA levels in patients received the DC-CIK cells treatment, their CA125 levels were significantly decreased after after the therapy (51.79 vs 36.52, P<0.01). A single-factor analysis found that lymph node as well as distant metastasis can significantly affect the survival time of these patients. The multivariate Cox model indicated that age, lymph node metastasis, and the CA125 level before treatment were significantly associated with the risk of cancer-related death in the patients.Conclusion: Autologous DC-CIK cells immunotherapy is a safe and feasible treatment for patients with moderate and advanced cervical cancer and it may improve the long-term survival of these patients.
Keywords:
Project Supported:
Project supported by the Science and Technology Development Project of Nanjing City（No. 201303040）
Clc Number:
